Title | Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Testo N, Olson LC, Subramaniyam S, Hanson T, Magro CM |
Journal | Am J Dermatopathol |
Volume | 38 |
Issue | 10 |
Pagination | 769-74 |
Date Published | 2016 Oct |
ISSN | 1533-0311 |
Keywords | Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Biopsy, Disease Progression, Fatal Outcome, Gene Rearrangement, Genes, Immunoglobulin Heavy Chain, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-myc, Skin Neoplasms, Time Factors |
Abstract | Aggressive extracutaneous B-cell lymphomas span the various stages of B-cell ontogeny and include B-cell lymphoblastic lymphoma, Burkitt lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. Diffuse large B-cell lymphomas represent the most common histologic subtype of non-Hodgkin lymphomas, comprising 30% of adult non-Hodgkin lymphomas in the United States. A distinctive form of diffuse large B-cell lymphoma is the double-hit lymphoma, with most cases exhibiting a combined MYC and BCL2 rearrangement, leading some hematopathologists to propose the term MYC/BCL2 lymphoma. More recently, MYC rearrangement with multiple copies/gain of BCL2 or multiple copies/gain of MYC with a BCL2 rearrangement have been described and exhibit a very similar clinical course to conventional double-hit lymphomas. We report the seventh case of diffuse large B-cell lymphoma exhibiting this distinct cytogenetic abnormality and the first reported case in the skin. The patient's clinical course was aggressive, succumbing to disease 18 months after his initial presentation. |
DOI | 10.1097/DAD.0000000000000607 |
Alternate Journal | Am J Dermatopathol |
PubMed ID | 27391453 |
Related Faculty:
Cynthia M. Magro, M.D.